10.52
+0.39(+3.85%)
Currency In USD
| Previous Close | 10.13 |
| Open | 10.15 |
| Day High | 10.72 |
| Day Low | 10.09 |
| 52-Week High | 24.16 |
| 52-Week Low | 5.9 |
| Volume | 1.94M |
| Average Volume | 5.16M |
| Market Cap | 1.13B |
| PE | -2.24 |
| EPS | -4.69 |
| Moving Average 50 Days | 10.96 |
| Moving Average 200 Days | 10.62 |
| Change | 0.39 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $458.14 as of August 22, 2025 at a share price of $10.125. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $501.24 as of August 22, 2025 at a share price of $10.125.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
GlobeNewswire Inc.
Jul 31, 2025 11:30 AM GMT
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 finan
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewswire Inc.
Jun 15, 2025 2:45 PM GMT
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demons
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
GlobeNewswire Inc.
May 18, 2025 11:25 AM GMT
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were p